Increasing Point-of-Care Testing Workload Addressed with New Integrated Systems Solution
|
By LabMedica International staff writers Posted on 17 Mar 2015 |

Image: The new Ecosystem solution and approach helps tackle data management challenges faced by point-of-care coordinators in the clinical laboratory (Photo courtesy of Siemens Healthcare Diagnostics).

Image: The point-of-care (POC) testing Ecosystem solution and approach encompasses eight core components: device management, operator management, quality control, compliance reporting, competency management, inventory management, remote monitoring, and mobile access (Image courtesy of Siemens Healthcare Diagnostics).
Challenges faced by clinical laboratory point-of-care (POC) coordinators can now be more efficiently tackled with an innovative approach developed as a new component of an informatics solution for managing in vitro diagnostics (IVD) analyzers and operators.
Siemens Healthcare Diagnostics, of Siemens AG (Berlin and Munich, Germany), now offers its new Ecosystem solution, an integrated component of its RAPIDComm Data Management System, an informatics solution that centrally manages Siemens IVD analyzers and operators.
Ecosystem, which encompasses eight core components, includes device management, operator management, quality control, compliance reporting, competency management, inventory management, remote monitoring, and mobile access.
“Siemens Healthcare Diagnostics has been carefully analyzing the POC market and is ready to provide a holistic approach to testing,” said Afia Boamah, product manager of Blood Gas, Stratus CS & POC IT S at Siemens Healthcare Diagnostics, “POC testing continues to grow at a rapid pace and there is a strong need to provide fast and reliable results.” “Although solutions for each of the 8 core components do exist individually, efficiently managing all aspects of a POC testing program requires close collaboration among hospitals, device manufacturers, and IT vendors. The Siemens POC Ecosystem helps to address this challenge by implementing an integrated solution which improves the efficiency and effectiveness of POC programs,” added A. Boamah.
Ecosystem takes the core needs of a POC program into consideration with a focus on helping POC coordinators improve control, effectiveness, and transparency. It manages secure access to POC devices, oversees quality control, manages staff training, and identifies and resolves issues - from any location via the remote access facility. This helps ensure manageability of instruments and consumables for potentially hundreds of testing devices. External compliance requirements are also met, while reducing costs.
“We are working hand-in-hand with healthcare providers to adapt to clinical environments making use of handheld IT devices such as tablets and smart phones. The Ecosystem solution allows POC data management from anywhere within a hospital using these devices, which improves the ability of POC coordinators to quickly and efficiently resolve issues. This has been highlighted by customers as a critical requirement in a fast-paced laboratory environment,” said A. Boamah.
Related Links:
Siemens
Siemens Healthcare
Siemens Healthcare Diagnostics, of Siemens AG (Berlin and Munich, Germany), now offers its new Ecosystem solution, an integrated component of its RAPIDComm Data Management System, an informatics solution that centrally manages Siemens IVD analyzers and operators.
Ecosystem, which encompasses eight core components, includes device management, operator management, quality control, compliance reporting, competency management, inventory management, remote monitoring, and mobile access.
“Siemens Healthcare Diagnostics has been carefully analyzing the POC market and is ready to provide a holistic approach to testing,” said Afia Boamah, product manager of Blood Gas, Stratus CS & POC IT S at Siemens Healthcare Diagnostics, “POC testing continues to grow at a rapid pace and there is a strong need to provide fast and reliable results.” “Although solutions for each of the 8 core components do exist individually, efficiently managing all aspects of a POC testing program requires close collaboration among hospitals, device manufacturers, and IT vendors. The Siemens POC Ecosystem helps to address this challenge by implementing an integrated solution which improves the efficiency and effectiveness of POC programs,” added A. Boamah.
Ecosystem takes the core needs of a POC program into consideration with a focus on helping POC coordinators improve control, effectiveness, and transparency. It manages secure access to POC devices, oversees quality control, manages staff training, and identifies and resolves issues - from any location via the remote access facility. This helps ensure manageability of instruments and consumables for potentially hundreds of testing devices. External compliance requirements are also met, while reducing costs.
“We are working hand-in-hand with healthcare providers to adapt to clinical environments making use of handheld IT devices such as tablets and smart phones. The Ecosystem solution allows POC data management from anywhere within a hospital using these devices, which improves the ability of POC coordinators to quickly and efficiently resolve issues. This has been highlighted by customers as a critical requirement in a fast-paced laboratory environment,” said A. Boamah.
Related Links:
Siemens
Siemens Healthcare
Latest Technology News
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Channels
Clinical Chemistry
view channel
Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) remains difficult to monitor because neurological decline can continue even after relapses stop. This progression independent of relapse activity is often subtle and may escape... Read more
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read moreMolecular Diagnostics
view channel
Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
Assessing early benefit from immunotherapy in advanced non-small cell lung cancer can be challenging because radiographic responses may take months to become clear. Early scans can also be difficult to... Read more
Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
Recurrent hepatocellular carcinoma (HCC) after surgery remains a major cause of poor outcomes and contributes to liver cancer’s rank as the world’s third leading cause of cancer death. The burden is particularly... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channelProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreIndustry
view channel
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







